Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ: VRTX )

467.28 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 43
Open 467.28
Bid (Size) 455.02 (2)
Ask (Size) 496.40 (1)
Prev. Close 467.28
Today's Range 467.28 - 467.28
52wk Range 335.82 - 486.43
Shares Outstanding 259,428,394
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 20 Years
Via Benzinga
3 Top Stocks I'd Buy Today and Hold Forever Without Any Hesitation
Evergreen business models make it easier to hold for the long run. 
Via The Motley Fool

Performance

YTD
+13.72%
+13.72%
1 Month
+4.80%
+4.80%
3 Month
+13.39%
+13.39%
6 Month
+16.75%
+16.75%
1 Year
+36.36%
+36.36%

More News

Read More
13 Analysts Have This To Say About Vertex Pharmaceuticals
Via Benzinga
Nvidia, AbbVie, Vertex Pharmaceuticals And An Oil Giant: CNBC's 'Final Trades'
Via Benzinga
3 Growth Stocks You Can Buy Right Now Without Any Hesitation
Via The Motley Fool
Vertex Presents Positive Long-Term Data On CASGEVY™ (exagamglogene autotemcel) at the 2024 Annual European Hematology Association (EHA) Congress
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Should Quality-Oriented Investors Explore VERTEX PHARMACEUTICALS INC (NASDAQ:VRTX)?
Via Chartmill
2 Healthcare Stocks to Buy Hand Over Fist in June
Via The Motley Fool
Alphabet To Rally Over 28%? Here Are 10 Top Analyst Forecasts For Tuesday
Via Benzinga
Healthcare And Biotech Investing: Breakthroughs In The Treatment Of Cancer At ASCO
Via Talk Markets
Cathie Wood Goes Bargain Hunting: 2 Stocks She Just Bought
Via The Motley Fool
Arcturus' Inhaled mRNA Therapeutic In Cystic Fibrosis Study Highlights Potential Amid Competitive Landscape: Analyst
Via Benzinga
$1000 Invested In Vertex Pharmaceuticals 5 Years Ago Would Be Worth This Much Today
Via Benzinga
This Is What Whales Are Betting On Vertex Pharmaceuticals
Via Benzinga
Analyst Expectations For Vertex Pharmaceuticals's Future
Via Benzinga
Vertex Presents New Data at the European Cystic Fibrosis Conference Demonstrating Significant Benefits of Treatment with TRIKAFTA®
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Large Cap BIopharmaceuticals Overview
Via Talk Markets
Topics Stocks
Exposures US Equities
3 No-Brainer Stocks to Buy in June
Via The Motley Fool
5 Top Stocks to Buy in June
Via The Motley Fool
While growth is established for NASDAQ:VRTX, the stock's valuation remains reasonable.
Via Chartmill
S&P 500 Giants Lead Five Healthy Stocks Near Buy Points
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
A Very Bullish Reversal Produces A Huge Batch Of Actionable Stocks
Via Talk Markets
Vertex Stock Recently Hit All-Time High, Leads 8 Top Performers New To IBD Stock Lists
Via Investor's Business Daily
Should Abbott and DexCom Investors Be Worried About Vertex Pharmaceuticals?
Via The Motley Fool
Arcturus Therapeutics' Early Cystic Fibrosis Trial Results Encouraging - Analyst Cautiously Optimistic
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.